Table 5.
Ongoing/recruiting major Phase III clinical trials in esophageal cancer (according to ClinicalTrials.gov)
| Name | Drug | Indication |
|---|---|---|
| BO27798 (NCT01450696) Worldwide |
Capecitabine/cisplatin (XP) ± trastuzumab | Locally advanced AC and stomach cancer |
| LOGiC (NCT00680901) Worldwide |
Capecitabine/oxaliplatin (CapeOx) ± lapatinib | Locally advanced AC and stomach cancer |
| POWER (NCT01627379) Germany |
Cisplatin/5-FU ± panitumumab | Locally advanced SCC |
| NCT00678535 Worldwide |
Capecitabine/cisplatin (XP) ± cetuximab | Locally advanced AC and stomach cancer |
| DIGEST (NCT01285557) Worldwide |
S-1/cisplatin versus 5-FU/cisplatin | Locally advanced AC and stomach cancer |
|
NCT01704690 China |
S-1/paclitaxel versus cisplatin/paclitaxel versus 5-FU/cisplatin | Locally advanced SCC or AC |
| FLOT-4 (AIO-STO-0210) Germany |
5-FU/leucovorin/oxaliplatin/docetaxel (FLOT) versus epirubicin/cisplatin/5-FU (ECF) | Locally advanced AC and stomach cancer |
| OXFORD-COG (NCT01243398) UK |
Gefitinib | 2nd-line therapy for SCC or AC |
| AIO STO-0111 (NCT01248403) Germany |
Paclitaxel + RAD001 (everolimus) | 2nd- and 3rd-line therapy for AC and stomach cancer |
| ICORG 10–14 (NCT01726452) Ireland |
Paclitaxel/carboplatin/radiation (CROSS protocol) (neoadjuvant) versus epirubicin/cisplatin/5-FU | Resectable, locally advanced AC |
|
NCT01216527 China |
(ECF, MAGIC protocol) (neo- and adjuvant) Navelbine/cisplatin/radiation (neoadjuvant) versus surgery alone | Resectable, locally advanced SCC |
| SAKK 75/08 (NCT01107639) Europe |
Docetaxel/cisplatin/cetuximab/radiation (neoadjuvant) ± cetuximab (adjuvant) | Resectable, locally advanced SCC or AC |
| RTOG-1010 (NCT01196390) USA |
Paclitaxel/carboplatin/radiation ± trastuzumab (neoadjuvant) + trastuzumab (adjuvant) | Resectable, locally advanced AC |
| ST03 (NCT00450203) UK |
Epirubicin/cisplatin/capecitabine (ECX) ± bevacizumab (neoadjuvant and adjuvant) | Resectable, locally advanced AC |
|
NCT01512589 USA |
Radiation (PBT) ± CT versus radiation (IMRT) ± CT | Potentially resectable or unresectable |
| FRE-FNCLCC-ACCORD-17-0707 (NCT00861094) France |
FOLFOX/radiation versus cisplatin/5-FU/radiation | SCC or AC Locally advanced SCC or AC |
| ESO2012-01 (NCT01591135) China |
Paclitaxel/5-FU/radiation versus cisplatin/5-FU/radiation | Locally advanced SCC |
| CONCORDE (NCT01348217) France |
FOLFOX-4/radiation (50 Gy) versus FOLFOX-4/radiation (66 Gy) |
Locally advanced SCC or AC |
| RTOG-0436 (NCT00655876) USA |
Paclitaxel/cisplatin/radiation ± cetuximab | Locally advanced SCC or AC |
| ESCC-307PLAH-XJM (NCT01752205) China |
Paclitaxel/radiation ± erlotinib | Locally advanced SCC |
| Shixiu – 1 (NCT00686114) China |
Paclitaxel/cisplatin/radiation ± erlotinib | Locally advanced SCC or AC |
Abbreviations: SCC, squamous cell carcinoma; AC, adenocarcinoma; XP, Xeloda (Roche, Basel, Switzerland) platinum; Gy, gray; PBT, proton beam therapy; CROSS, Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study; MAGIC, Medical Research Council Adjuvant Gastric Infusional Chemotherapy; SAKK, Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; RTOG, Radiation Therapy Oncology Group; IMRT, intensity-modulated radiation therapy; FOLFOX, 5-FU/oxaliplatin; S-1, oral fluoropyramidine; CT, chemotherapy; 5-FU, 5-fluorouracil.